This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Epilepsy
and you are
between 20 and 65
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to investigate the pharmacokinetics of single oral doses of ezogabine/retigabine and the primary metabolite (NAMR) in healthy male and female Taiwanese volunteers. Subjects will receive four separate doses of ezogabine/retigabine tablets: 50 mg, 100 mg, 200 mg and 400 mg administered once orally. Blood samples will be obtained at pre-defined timepoints over the duration of the study to determine the concentration of ezogabine/retigabine and NAMR. Safety assessments will include measurements of vital signs, collection of adverse events, clinical laboratory tests and the Columbia Suicide Severity Rating Scale.

Provided treatments

  • Drug: 50mg Ezogabine/retigabine
  • Drug: 100mg Ezogabine/retigabine
  • Drug: 200mg Ezogabine/retigabine
  • Drug: 400mg Ezogabine/retigabine

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01462669. The sponsor of the trial is GlaxoSmithKline and it is looking for 1 volunteers for the current phase.
Official trial title:
An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects